Prothena ( ($PRTA) ) has provided an update. On December 10, 2025, Paula Cobb announced her resignation from Prothena Corporation plc’s Board of ...

System1, Inc. ("System1" or the "Company"), today announced that it was notified by the New York Stock Exchange (the "NYSE") that it is currently not in compliance with Section 802.01B of the NYSE ...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational ...

Prothena’s fair value estimate has been nudged higher from $18.33 to $20.33 per share as analysts grow more confident in the company’s partnered pipeline and its potential to drive stronger long term ...

Protego Biopharma is poised to start pivotal trials of its amyloid light-chain (AL) amyloidosis drug candidate, thanks to a ...

Fintel reports that on December 1, 2025, Citizens maintained coverage of Prothena (NasdaqGS:PRTA) with a Market Outperform ...

The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that ...

Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a ...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported ...

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash ...